DEBUONO LAUREEN 4
4 · Rani Therapeutics Holdings, Inc. · Filed Dec 17, 2024
Insider Transaction Report
Form 4
DEBUONO LAUREEN
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2024-12-16−101,276→ 0 totalExercise: $2.84From: 2024-05-25Exp: 2033-05-24→ Class A Common Stock (101,276 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2024-12-16−18,875→ 0 totalExercise: $2.84Exp: 2031-07-28→ Class A Common Stock (18,875 underlying) - Award
Stock Option (Right to Buy)
2024-12-16+18,875→ 135,896 totalExercise: $9.44Exp: 2031-07-28→ Class A Common Stock (18,875 underlying) - Award
Stock Option (Right to Buy)
2024-12-16+101,276→ 101,276 totalExercise: $4.11From: 2024-05-25Exp: 2033-05-24→ Class A Common Stock (101,276 underlying)
Footnotes (3)
- [F1]On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $4.11 per share. There is no change to the expiration dates or the vesting schedule of the options.
- [F2]The shares subject to the option vested as follows: 1/3rd of the shares subject to the option vested on April 20, 2022; and 1/36th of the shares subject to the option vested monthly over the following two years.
- [F3]On December 16, 2024, the exercise price of the stock options has been amended to increase the exercise price to $9.44 per share. There is no change to the expiration dates or the vesting schedule of the options.